• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

采用美国临床和实验室标准协会(CLSI)方法及流式细胞术对新型隐球菌格鲁比变种AFLP1/VNI和加蒂隐球菌AFLP6/VGII进行两性霉素B的体外药敏试验。

In vitro susceptibility testing of amphotericin B for Cryptococcus neoformans variety grubii AFLP1/VNI and Cryptococcus gattii AFLP6/VGII by CLSI and flow cytometry.

作者信息

Morales Bernardina Penarrieta, Trilles Luciana, Bertho Álvaro Luiz, Junior Ivan Neves, de Oliveira Raquel de Vasconcellos Carvalhaes, Wanke Bodo, Lazéra Márcia dos Santos

机构信息

Laboratory Medical Mycology, National Institute of Infectious Diseases Evandro Chagas Oswaldo Cruz Foundation (INI-FIOCRUZ), Rio de Janeiro, Brazil.

出版信息

Mycoses. 2015 May;58(5):273-9. doi: 10.1111/myc.12310. Epub 2015 Mar 10.

DOI:10.1111/myc.12310
PMID:25756839
Abstract

Cryptococcus neoformans var. grubii AFLP1/VNI is the main causative agent of cryptococcosis associated with AIDS in the world. Cryptococcus gattii AFLP6/VGII causes mainly endemic primary infection in immunocompetent hosts. To determine the minimum inhibitory concentrations (MICs) of C. neoformans var. grubii AFLP1/VNI and C. gattii AFLP6/VGII against amphotericin B (AMB) in a short period of time, flow cytometry (FCM) with FUN-1 fluorochrome was used to compare with broth microdilution method (CLSI M27-A3). The minimum incubation period was evaluated by minimum fungicidal concentration procedure. Seventeen clinical isolates of C. neoformans var. grubii AFLP1/VNI and 18 of C. gattii AFLP6/VGII were analysed. The time for the determination of MICs by FCM was 2 h against 72 h by CLSI M27-A3 and the comparison of MIC showed a positive significant correlation (P = 0.048). It is important to highlight the role of the FCM as an alternative method to determine the MICs for AMB in within a day, with positive cost-benefit.

摘要

新型隐球菌格鲁比变种AFLP1/VNI是全球与艾滋病相关的隐球菌病的主要病原体。加蒂隐球菌AFLP6/VGII主要引起免疫功能正常宿主的地方性原发性感染。为了在短时间内确定新型隐球菌格鲁比变种AFLP1/VNI和加蒂隐球菌AFLP6/VGII对两性霉素B(AMB)的最低抑菌浓度(MIC),使用带有FUN-1荧光染料的流式细胞术(FCM)与肉汤微量稀释法(CLSI M27-A3)进行比较。通过最低杀菌浓度程序评估最短培养期。分析了17株新型隐球菌格鲁比变种AFLP1/VNI临床分离株和18株加蒂隐球菌AFLP6/VGII临床分离株。FCM测定MIC的时间为2小时,而CLSI M27-A3为72小时,MIC比较显示出显著正相关(P = 0.048)。重要的是要强调FCM作为一种替代方法在一天内确定AMB的MIC的作用,具有积极的成本效益。

相似文献

1
In vitro susceptibility testing of amphotericin B for Cryptococcus neoformans variety grubii AFLP1/VNI and Cryptococcus gattii AFLP6/VGII by CLSI and flow cytometry.采用美国临床和实验室标准协会(CLSI)方法及流式细胞术对新型隐球菌格鲁比变种AFLP1/VNI和加蒂隐球菌AFLP6/VGII进行两性霉素B的体外药敏试验。
Mycoses. 2015 May;58(5):273-9. doi: 10.1111/myc.12310. Epub 2015 Mar 10.
2
Comparative antifungal susceptibility analyses of Cryptococcus neoformans VNI and Cryptococcus gattii VGII from the Brazilian Amazon Region by the Etest, Vitek 2, and the Clinical and Laboratory Standards Institute broth microdilution methods.巴西亚马逊地区新型隐球菌 VNI 和格特隐球菌 VGII 的 Etest、Vitek 2 和临床与实验室标准协会微量肉汤稀释法比较抗真菌药敏分析。
Med Mycol. 2019 Oct 1;57(7):864-873. doi: 10.1093/mmy/myy150.
3
Determination of the minimum inhibitory concentration of Cryptococcus neoformans and Cryptococcus gattii against fluconazole by flow cytometry.用流式细胞术测定新型隐球菌和格特隐球菌对氟康唑的最小抑菌浓度。
Med Mycol. 2014 Jan;52(1):90-8. doi: 10.3109/13693786.2013.806827.
4
Molecular typing and in vitro antifungal susceptibility of Cryptococcus spp from patients in Midwest Brazil.巴西中西部地区患者隐球菌属的分子分型及体外抗真菌药敏试验
J Infect Dev Ctries. 2014 Aug 13;8(8):1037-43. doi: 10.3855/jidc.4446.
5
In vitro antifungal susceptibility profiles and genotypes of 308 clinical and environmental isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii serotype B from north-western India.来自印度西北部的 308 株新型隐球菌和格特隐球菌 B 型临床和环境分离株的体外抗真菌药敏谱和基因型。
J Med Microbiol. 2011 Jul;60(Pt 7):961-967. doi: 10.1099/jmm.0.029025-0. Epub 2011 Mar 10.
6
Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for amphotericin B and flucytosine.新型隐球菌-格特隐球菌种复合体:两性霉素 B 和氟胞嘧啶野生型药敏终点分布及流行病学折点的国际研究。
Antimicrob Agents Chemother. 2012 Jun;56(6):3107-13. doi: 10.1128/AAC.06252-11. Epub 2012 Mar 5.
7
Molecular epidemiology and in vitro antifungal susceptibility testing of 108 clinical Cryptococcus neoformans sensu lato and Cryptococcus gattii sensu lato isolates from Denmark.对来自丹麦的108株新型隐球菌复合体和格特隐球菌复合体临床分离株进行的分子流行病学及体外抗真菌药敏试验
Mycoses. 2016 Sep;59(9):576-84. doi: 10.1111/myc.12507. Epub 2016 Apr 8.
8
A flow cytometry method for testing the susceptibility of Cryptococcus spp. to amphotericin B.一种用于检测隐球菌属对两性霉素B敏感性的流式细胞术方法。
Rev Iberoam Micol. 2015 Jul-Sep;32(3):159-63. doi: 10.1016/j.riam.2014.06.004. Epub 2014 Oct 27.
9
Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole.新型隐球菌-格特隐球菌种复合体:氟康唑、伊曲康唑、泊沙康唑和伏立康唑野生型药敏终点分布和流行病学折点的国际研究。
Antimicrob Agents Chemother. 2012 Nov;56(11):5898-906. doi: 10.1128/AAC.01115-12. Epub 2012 Sep 4.
10
Cryptococcus neoformans and C. gattii isolates from both HIV-infected and uninfected patients: antifungal susceptibility and outcome of cryptococcal disease.来自HIV感染和未感染患者的新型隐球菌和格特隐球菌分离株:抗真菌药敏性及隐球菌病的转归
Rev Inst Med Trop Sao Paulo. 2017;59:e49. doi: 10.1590/S1678-9946201759049. Epub 2017 Aug 3.

引用本文的文献

1
The status of cryptococcosis in Latin America.拉丁美洲隐球菌病的现状。
Mem Inst Oswaldo Cruz. 2018;113(7):e170554. doi: 10.1590/0074-02760170554. Epub 2018 Apr 5.